Pokarna Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 22, 2025, 4:41 am

Competitors of Pokarna Ltd

All Competitor Stocks of Pokarna Ltd

Quarterly Result

Last Updated: August 1, 2025, 3:11 pm

Below is a detailed analysis of the quarterly data for Pokarna Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 171.00 Cr.. The value appears to be declining and may need further review. It has decreased from 263.00 Cr. (Mar 2025) to 171.00 Cr., marking a decrease of 92.00 Cr..
• For Expenses, as of Jun 2025, the value is 116.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.00 Cr. (Mar 2025) to 116.00 Cr., marking a decrease of 46.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 55.00 Cr., marking a decrease of 46.00 Cr..
• For OPM %, as of Jun 2025, the value is 32.00%. The value appears to be declining and may need further review. It has decreased from 38.00% (Mar 2025) to 32.00%, marking a decrease of 6.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
• For Interest, as of Jun 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 38.00 Cr.. The value appears to be declining and may need further review. It has decreased from 82.00 Cr. (Mar 2025) to 38.00 Cr., marking a decrease of 44.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 25.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 31.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 9.12. The value appears to be declining and may need further review. It has decreased from 19.00 (Mar 2025) to 9.12, marking a decrease of 9.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 2:17 pm

Growth

Last Updated: September 5, 2025, 12:20 pm

Balance Sheet

Last Updated: September 10, 2025, 2:15 pm

Below is a detailed analysis of the balance sheet data for Pokarna Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
• For Reserves, as of Mar 2025, the value is 772.00 Cr.. The value appears strong and on an upward trend. It has increased from 586.00 Cr. (Mar 2024) to 772.00 Cr., marking an increase of 186.00 Cr..
• For Borrowings, as of Mar 2025, the value is 370.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 401.00 Cr. (Mar 2024) to 370.00 Cr., marking a decrease of 31.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 256.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 221.00 Cr. (Mar 2024) to 256.00 Cr., marking an increase of 35.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,403.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,215.00 Cr. (Mar 2024) to 1,403.00 Cr., marking an increase of 188.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 793.00 Cr.. The value appears strong and on an upward trend. It has increased from 710.00 Cr. (Mar 2024) to 793.00 Cr., marking an increase of 83.00 Cr..
• For CWIP, as of Mar 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 65.00 Cr. (Mar 2024) to 41.00 Cr., marking a decrease of 24.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 569.00 Cr.. The value appears strong and on an upward trend. It has increased from 440.00 Cr. (Mar 2024) to 569.00 Cr., marking an increase of 129.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,403.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,215.00 Cr. (Mar 2024) to 1,403.00 Cr., marking an increase of 188.00 Cr..

Notably, the Reserves (772.00 Cr.) exceed the Borrowings (370.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Pokarna Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 60.49. This value is within the healthy range. It has increased from 28.18 (Mar 24) to 60.49, marking an increase of 32.31.
• For Diluted EPS (Rs.), as of Mar 25, the value is 60.49. This value is within the healthy range. It has increased from 28.18 (Mar 24) to 60.49, marking an increase of 32.31.
• For Cash EPS (Rs.), as of Mar 25, the value is 74.74. This value is within the healthy range. It has increased from 41.91 (Mar 24) to 74.74, marking an increase of 32.83.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 250.93. It has increased from 191.05 (Mar 24) to 250.93, marking an increase of 59.88.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 250.93. It has increased from 191.05 (Mar 24) to 250.93, marking an increase of 59.88.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 300.00. It has increased from 221.78 (Mar 24) to 300.00, marking an increase of 78.22.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 111.93. This value is within the healthy range. It has increased from 71.34 (Mar 24) to 111.93, marking an increase of 40.59.
• For PBIT / Share (Rs.), as of Mar 25, the value is 97.68. This value is within the healthy range. It has increased from 57.61 (Mar 24) to 97.68, marking an increase of 40.07.
• For PBT / Share (Rs.), as of Mar 25, the value is 85.72. This value is within the healthy range. It has increased from 45.03 (Mar 24) to 85.72, marking an increase of 40.69.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 60.49. This value is within the healthy range. It has increased from 28.18 (Mar 24) to 60.49, marking an increase of 32.31.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 60.49. This value is within the healthy range. It has increased from 28.18 (Mar 24) to 60.49, marking an increase of 32.31.
• For PBDIT Margin (%), as of Mar 25, the value is 37.31. This value is within the healthy range. It has increased from 32.16 (Mar 24) to 37.31, marking an increase of 5.15.
• For PBIT Margin (%), as of Mar 25, the value is 32.56. This value exceeds the healthy maximum of 20. It has increased from 25.97 (Mar 24) to 32.56, marking an increase of 6.59.
• For PBT Margin (%), as of Mar 25, the value is 28.57. This value is within the healthy range. It has increased from 20.30 (Mar 24) to 28.57, marking an increase of 8.27.
• For Net Profit Margin (%), as of Mar 25, the value is 20.16. This value exceeds the healthy maximum of 10. It has increased from 12.70 (Mar 24) to 20.16, marking an increase of 7.46.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.16. This value exceeds the healthy maximum of 20. It has increased from 12.70 (Mar 24) to 20.16, marking an increase of 7.46.
• For Return on Networth / Equity (%), as of Mar 25, the value is 24.10. This value is within the healthy range. It has increased from 14.74 (Mar 24) to 24.10, marking an increase of 9.36.
• For Return on Capital Employeed (%), as of Mar 25, the value is 26.81. This value is within the healthy range. It has increased from 17.79 (Mar 24) to 26.81, marking an increase of 9.02.
• For Return On Assets (%), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 7.18 (Mar 24) to 13.36, marking an increase of 6.18.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.27, marking a decrease of 0.24.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.65 (Mar 24) to 0.42, marking a decrease of 0.23.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has increased from 0.59 (Mar 24) to 0.71, marking an increase of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 1.93, marking a decrease of 0.04.
• For Quick Ratio (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 1.36, marking an increase of 0.16.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.80. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 5.80, marking an increase of 4.42.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 20. It has decreased from 2.12 (Mar 24) to 0.99, marking a decrease of 1.13.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 20. It has decreased from 1.43 (Mar 24) to 0.80, marking a decrease of 0.63.
• For Earning Retention Ratio (%), as of Mar 25, the value is 99.01. This value exceeds the healthy maximum of 70. It has increased from 97.88 (Mar 24) to 99.01, marking an increase of 1.13.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 99.20. This value exceeds the healthy maximum of 70. It has increased from 98.57 (Mar 24) to 99.20, marking an increase of 0.63.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 9.35. This value is within the healthy range. It has increased from 5.67 (Mar 24) to 9.35, marking an increase of 3.68.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.05. This value is within the healthy range. It has increased from 3.34 (Mar 24) to 6.05, marking an increase of 2.71.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,170.68. It has increased from 1,626.50 (Mar 24) to 4,170.68, marking an increase of 2,544.18.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.48. This value exceeds the healthy maximum of 3. It has increased from 2.37 (Mar 24) to 4.48, marking an increase of 2.11.
• For EV / EBITDA (X), as of Mar 25, the value is 12.02. This value is within the healthy range. It has increased from 7.35 (Mar 24) to 12.02, marking an increase of 4.67.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 1.92 (Mar 24) to 4.26, marking an increase of 2.34.
• For Retention Ratios (%), as of Mar 25, the value is 99.00. This value exceeds the healthy maximum of 70. It has increased from 97.87 (Mar 24) to 99.00, marking an increase of 1.13.
• For Price / BV (X), as of Mar 25, the value is 5.10. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 5.10, marking an increase of 2.87.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 1.92 (Mar 24) to 4.26, marking an increase of 2.34.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.04, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness